Protection From Demyelination by the Novel Adenosine Dual A<sub>2A</sub>/A<sub>2B</sub> Receptor Antagonist P626 in EAE and Cultured Oligodendrocyte Precursor Cells.

A more detailed analysis of the effect on motor symptoms showed that, although not significant, P626‐treated EAE mice showed a trend toward a prolonged time to disease onset (Figure 2F ) and to reach peak clinical score (Figure 2G ) than untreated EAE mice, along with a tendency to reduced maximum scores (Figure 2H ).

also in 53,322 other papers